Company / Accounts Receivable
Evolent Health, Inc. Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$309.9M
FY2025
5-year range
$130.6M / $446.7M
FY2021-FY2025
Trend
-25.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has fluctuated over the past 10 years, ranging from $41M in FY2016 to $447M in FY2023.
Based on SEC 10-K filings.
$310M in FY2025 with a 5-year CAGR of +20.1%.
Declined from $447M to $310M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +6.8%
- 5-Year CAGR
- +20.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +20.1%, indicating consistent growth.
- In FY2025, accounts receivable decreased 25.3% year-over-year.
- Peak accounts receivable was recorded in FY2023.
- Lowest accounts receivable in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -0.84 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $309.9M | -25.3% |
| FY2024 | $414.7M | -7.2% |
| FY2023 | $446.7M | +75.4% |
| FY2022 | $254.7M | +95.0% |
| FY2021 | $130.6M | +5.3% |
| FY2020 | $124.1M | +64.0% |
| FY2019 | $75.7M | -5.7% |
| FY2018 | $80.2M | +63.9% |
| FY2017 | $48.9M | +20.5% |
| FY2016 | $40.6M | +99.4% |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026